SPARC and diffuse large B-cell lymphoma: The current results supported low expression of SPARC might predict Adr resistance in GC based on data derived from both GSEA and molecular experiment, and it was consistent with the findings in patients treated by Adr that higher SPARC expression predicted higher pathological complete remission rate in breast cancer and longer OS in diffuse large B-cell lymphoma, respectively [26, 27].